Clinical trials: MSI-H
Colorectal Cancer (MSI-H), Molecular Residual Disease
Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD
This study aims to evaluate whether plasma molecular residual disease (MRD), assessed using circulating tumor DNA (ctDNA), can help optimize the duration of immunotherapy in patients with metastatic microsatellite…
- Trial name
- NCT07775950
- Testing
- Discontinue NA Treatment, Continued Immunotherapy, Observation
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Gastric, Colorectal Adenocarcinoma
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
Objective of this study to evaluate 1-year disease-free survival in patients with dMMR/MSI-H or POLE/POLD1 gene mutations with gastric or esophagus-gastric junctional adenocarcinoma or colorectal adenocarcinoma after…
- Trial name
- NCT06118658
- Testing
- tislelizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- China Medical University, China